Your browser doesn't support javascript.
loading
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
De Mattos-Arruda, Leticia; Ng, Charlotte K Y; Piscuoglio, Salvatore; Gonzalez-Cao, Maria; Lim, Raymond S; De Filippo, Maria R; Fusco, Nicola; Schultheis, Anne M; Ortiz, Carolina; Viteri, Santiago; Arias, Alexandra; Macedo, Gabriel S; Oliveira, Mafalda; Gomez, Patricia; Teixidó, Cristina; Nuciforo, Paolo; Peg, Vicente; Saura, Cristina; Ramon Y Cajal, Santiago; Casas, Francesc Tresserra; Weigelt, Britta; Cortes, Javier; Seoane, Joan; Reis-Filho, Jorge S.
Afiliação
  • De Mattos-Arruda L; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ng CKY; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
  • Piscuoglio S; Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Gonzalez-Cao M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lim RS; Institute of Pathology, University Hospital Basel, Basel, Switzerland.
  • De Filippo MR; Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Fusco N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Schultheis AM; Institute of Pathology, University Hospital Basel, Basel, Switzerland.
  • Ortiz C; Quirón Dexeus University Hospital, Barcelona, Spain.
  • Viteri S; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Arias A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Macedo GS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Oliveira M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Gomez P; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
  • Teixidó C; Quirón Dexeus University Hospital, Barcelona, Spain.
  • Nuciforo P; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
  • Peg V; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Saura C; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
  • Ramon Y Cajal S; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
  • Casas FT; Quirón Dexeus University Hospital, Barcelona, Spain.
  • Weigelt B; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
  • Cortes J; Vall d'Hebron Institute of Research, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Seoane J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
  • Reis-Filho JS; Vall d'Hebron Institute of Research, Vall d'Hebron University Hospital, Barcelona, Spain.
Oncotarget ; 9(29): 20617-20630, 2018 Apr 17.
Article em En | MEDLINE | ID: mdl-29755676
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos